Exhibit 99.1

Omega Protein Announces First Quarter 2015 Financial Results

HOUSTON, TX – May 11, 2015 – Omega Protein Corporation (NYSE:OME), a nutritional product company and a leading integrated provider of specialty oils, essential fatty acids and specialty protein products, today reported financial results for the first quarter ended March 31, 2015.

First Quarter Highlights

“We continued our movement towards becoming a more balanced nutrition company in the first quarter with our human nutrition segment generating a record $35 million of revenues,” commented Bret Scholtes, Omega Protein’s President and Chief Executive Officer. “As we expected, our animal nutrition segment experienced lower sales volumes primarily due to lower beginning inventory levels. Looking ahead, our team remains focused on further integrating our recent acquisitions to drive growth and diversification in our nutrition businesses.”

First Quarter 2015 Results

The Company's revenues increased 13% from $63.5 million in the same period last year to $71.6 million. This increase was due to growth in human nutrition revenues of $26.6 million, partially offset by a decline in animal nutrition revenues of $18.4 million. The increase in human nutrition revenues was largely due to the addition of Bioriginal Food & Science Corp. (“Bioriginal”), which was acquired in September 2014. The decrease in animal nutrition revenues was due to lower sales volumes of 76% and 12% for the Company’s fish oil and fish meal, respectively, partially offset by increased sales prices of 56% and 6% for the Company’s fish oil and fish meal, respectively. The composition of revenues by nutritional product line for the first quarter of 2015 was 49% dietary supplements and food, 37% fish meal, 13% fish oil and 1% fish solubles and other.

First quarter of 2015 revenues decreased 30% from $102.5 million in the fourth quarter of 2014 to $71.6 million. This decrease was due to a $31.3 million decline in animal nutrition revenues, partially offset by a $0.5 million increase in human nutrition revenues. The decrease in animal nutrition revenues was primarily due to lower fish meal and fish oil volumes of 46% and 66%, respectively, partially offset by higher fish meal and fish oil sales prices of 7% and 30%, respectively.

The Company reported gross profit of $14.8 million, or 20.7% as a percentage of revenues, for the first quarter of 2015, versus $20.5 million, or 32.3% as a percentage of revenues, in the first quarter of 2014. The decrease in gross profit as a percentage of revenues was due to corresponding reductions in both the animal and human nutrition segments. Animal segment gross profit as a percentage of revenues declined from 34.6% to 28.6%, due primarily to a higher cost per unit for the most recent season’s production, as well as a $0.4 million expense for fuel hedge ineffectiveness in the first quarter of 2015. Human nutrition gross profit as a percentage of revenues decreased from 16.9% to 12.2% due primarily to changes in product mix and a lower gross profit as a percentage of revenues for protein products.

Compared to the fourth quarter of 2014, first quarter gross profit decreased from $22.5 million, or 22.0% as a percentage of revenues, to $14.8 million, or 20.7% as a percentage of revenues, due primarily to lower animal nutrition revenues. Animal nutrition gross profit as a percentage of revenues was nearly unchanged, decreasing from 28.7% to 28.6%. Human nutrition segment gross profit as a percentage of revenues increased from 8.6% to 12.2% due primarily to improved results from protein products.

Selling, general and administrative expense (“SG&A”) for the first quarter increased by $3.3 million to $9.4 million compared the first quarter of 2014, primarily as a result of the Bioriginal acquisition. SG&A expense increased $0.7 million from $8.7 million in the fourth quarter of 2014.

In the fourth quarter of 2013, the Company closed its menhaden fish processing plant located in Cameron, Louisiana and re-deployed certain vessels from that facility to the Company’s other Gulf Coast facilities. In conjunction with the closure, the Company incurred charges of $0.6 million and $1.3 million in the first quarters of 2015 and 2014, respectively.

Loss on foreign currency related to Bioriginal was $0.5 million for the first quarter of 2015; there was no gain or loss on foreign currency in the first quarter of 2014.

The first quarter of 2015 effective tax rate was 36.9% compared to 33.9% in the first quarter of 2014 and 46.5% in the fourth quarter of 2014. The first quarter of 2015 effective tax rate reflected the impact of non-deductible expenses and the fourth quarter of 2014 effective tax rate reflected lower deductions resulting from tax rules enacted during the quarter.

Net income for the first quarter of 2015 was $1.7 million ($0.08 per diluted share) compared to $8.0 million ($0.37 per diluted share) in the same period last year and $3.2 million ($0.14 per diluted share) in the fourth quarter of 2014. Excluding adjustments for certain items, net income for the first quarter of 2015 would have been $2.6 million ($0.12 per diluted share), compared to $9.0 million ($0.42 per diluted share) in the same period last year and $7.8 million ($0.35 per diluted share) for the fourth quarter of 2014.

Adjusted EBITDA totaled $10.4 million for the first quarter of 2015, compared to $19.1 million for the same period last year and $19.7 million for the fourth quarter of 2014.

Balance Sheet

The Company's March 31, 2015 cash balance decreased $1.2 million from December 31, 2014 to $0.2 million, and total debt increased $4.4 million from December 31, 2014 to $39.7 million on March 31, 2015, due primarily to business seasonality and capital expenditures. Stockholders' equity increased $1.5 million to $267.4 million as of March 31, 2015 compared to $265.9 million as of December 31, 2014.

Conference Call Information

Omega Protein will host a conference call on its first quarter 2015 financial results at 8:30 a.m., Eastern Time, on Tuesday, May 12, 2015. The Company’s senior management team will be available to discuss recent financial results and current business trends as well as respond to questions.

Please dial (877) 407-3982 domestically or (201) 493-6780 internationally to join the call. Interested parties may also listen to the webcast live over the Internet at www.omegaprotein.com.

A webcast replay of the conference call and the prepared remarks will be available beginning shortly after the conclusion of the call at www.omegaprotein.com and will be available for 30 days. A telephonic replay of the conference call will be available through May 26, 2015. Domestic listeners can dial (877) 870-5176, and international listeners may dial (858) 384-5517. The replay access code is 13607881.

About Omega Protein Corporation

Omega Protein Corporation (NYSE: OME) is a century old nutritional product company that develops, produces and delivers healthy products throughout the world to improve the nutritional integrity of foods, dietary supplements and animal feeds. Omega Protein's mission is to help people lead healthier lives with better nutrition through sustainably sourced ingredients such as highly-refined specialty oils and essential fatty acids, specialty protein products and nutraceuticals.

The Company operates eight manufacturing facilities located in the United States, Canada and Europe. The Company also operates more than 30 vessels to harvest menhaden, a fish abundantly found off of the coasts of the Atlantic Ocean and Gulf of Mexico.

For More Information

Visit Omega Protein at www.omegaprotein.com, follow us on Twitter at https://twitter.com/omegaprotein, or find us on LinkedIn at https://www.linkedin.com/company/omega-protein-inc.

Forward Looking Statements

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: The statements contained in this press release that are not historical facts are forward-looking statements that involve a number of risks and uncertainties. Forward-looking information may be based on projections, predictions and estimates. Some statements in this press release may be forward-looking and use words like “may,” “may not,” “believes,” “do not believe,” “expects,” “do not expect,” “anticipates,” “do not anticipate,” “see,” “do not see,” “should,” or other similar expressions. The actual results of future events described in any of these forward-looking statements could differ materially from those stated in the forward-looking statements. Important factors that could cause actual results to be materially different from those forward-looking statements include, among others: (1) the Company’s ability to meet its raw material requirements through its annual menhaden harvest, which is subject to fluctuations due to natural conditions over which the Company has no control, such as varying fish population, fish oil yields, adverse weather conditions, natural and other disasters and disease; (2) the impact of laws and regulations that may be enacted that may restrict the Company’s operations or the sale of the Company’s products or increase the cost of compliance; (3) the impact of worldwide supply and demand relationships on prices for the Company’s products; (4) the Company’s expectations regarding demand and pricing for its products proving to be incorrect, and the effect of forward sales of products on the Company’s financial results; (5) fluctuations in the Company’s quarterly operating results due to the seasonality of the Company’s business, estimates of standard cost for inventory and subsequent adjustments to such costs, and the Company’s deferral of inventory sales based on worldwide prices for competing products; (6) the Company’s ability to realize the anticipated benefits from its acquisitions in the human nutrition business, and specifically, to integrate successfully its most recent acquisition of Bioriginal; (7) the Company’s expectations regarding Nutegrity or Bioriginal, their future prospects and the dietary supplement market or the human health and wellness segment generally, proving to be incorrect; (8) increase in the price and shortage of key raw materials that could adversely affect Bioriginal’s and Nutegrity’s businesses; and (9) the cost of compliance or potential restrictions on sales caused by laws and regulations regarding fish meal or oil importation into foreign jurisdictions. Other factors are described in further detail in the Company’s filings with the Securities and Exchange Commission, including its reports on Form 10-K, Form 10-Q and Form 8-K. Except as required by law, the Company expressly disclaims any intention or obligation to revise or update any forward-looking information whether as a result of new information, future events or otherwise.

Contact:
Investor Relations
(713) 623-0060
hq@omegahouston.com

OMEGA PROTEIN CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET

(Dollars in thousands, except par value amounts)

OMEGA PROTEIN CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

(In thousands, except per share amounts)

OMEGA PROTEIN CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(Dollars in thousands)

The tables below present information about reported segments for the three months ended March 31, 2015 and 2014 (in thousands). It should be noted that all cash and cash equivalent balances have been included in the identifiable assets of the unallocated segment.

(1) Excludes revenue from internal customers of $0.4 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

(2) Excludes revenue from internal customers of $0.7 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

Adjusted EBITDA to Net Income Reconciliation

The following table (in thousands) provides a reconciliation of Adjusted EBITDA, a non-GAAP (Generally Accepted Accounting Principles) financial measure, to net income, the most directly comparable financial measure calculated and presented in accordance with GAAP, for the three months ended for the three months ended March 31, 2015, December 31, 2014 and March 31, 2014:

Adjusted EBITDA represents net income before interest expense, income tax, depreciation and amortization, loss related to plant closure, impairment of intangible assets, acquisition post-closing consideration, acquisition costs and inventory adjustment and loss (gain) on disposal of assets. The Company has reported Adjusted EBITDA because it believes Adjusted EBITDA is a measure commonly reported and widely used by investors as an indicator of a company's operating performance. The Company believes Adjusted EBITDA assists such investors in comparing a company's performance on a consistent basis. Adjusted EBITDA is not a calculation based on GAAP and should not be considered an alternative to net income in measuring our performance or used as an exclusive measure of cash flow because it does not consider the impact of working capital changes, capital expenditures, debt principal reductions and other sources and uses of cash which are disclosed in our consolidated statements of cash flows. Investors should carefully consider the specific items included in our computation of Adjusted EBITDA. While Adjusted EBITDA has been disclosed herein to permit a more complete comparative analysis of our operating performance relative to other companies, investors should be cautioned that Adjusted EBITDA as reported by us may not be comparable in all instances to Adjusted EBITDA as reported by us or by other companies. Adjusted EBITDA amounts may not be fully available for management's discretionary use, due to certain requirements to conserve funds for capital expenditures, debt service and other commitments, and therefore management relies primarily on our GAAP results. Adjusted EBITDA is not intended to represent net income as defined by GAAP and such information should not be considered as an alternative to net income, cash flow from operations or any other measure of performance prescribed by GAAP in the United States.

Adjusted Net Income and Diluted Earnings Per Share to Net Income Reconciliation

The following table (in thousands, except per share amounts) provides a reconciliation of Adjusted Net Income and Diluted Earnings Per Share, non-GAAP (Generally Accepted Accounting Principles) financial measures, to net income, the most directly comparable financial measure calculated and presented in accordance with GAAP, for the three months ended March 31, 2015, December 31, 2014 and March 31, 2014:

Adjusted net income and Adjusted diluted earnings per share represent net income and diluted earnings per share without loss related to plant closure, impairment of intangible assets, acquisition post-closing consideration, acquisition costs and inventory adjustment and loss (gain) on disposal of assets and taxes associated with these items. The Company has reported Adjusted net income and Adjusted diluted earnings per share because it believes these measures are widely used by investors as an indicator of a company’s operating performance. The Company believes Adjusted net income and Adjusted diluted earnings per share assist investors in comparing a company's performance on a consistent basis. Adjusted net income and Adjusted diluted earnings per share are not calculations based on GAAP and should not be considered alternatives to net income or diluted earnings per share in measuring our performance. Investors should carefully consider the specific items included in our computation of Adjusted net income and Adjusted diluted earnings per share. While Adjusted net income and Adjusted diluted earnings per share has been disclosed herein to permit a more complete comparative analysis of our operating performance across time periods and relative to other companies, investors should be cautioned that these measures as reported by us may not be comparable in all instances to Adjusted net income and Adjusted diluted earnings per share as reported by us or by other companies. Adjusted net income and Adjusted diluted earnings per share are not intended to represent net income or diluted earnings per share as defined by GAAP and such information should not be considered as an alternative to net income, diluted earnings per share or any other measure of performance prescribed by GAAP in the United States.

8